文献速递肝病

酒精使用障碍对丙型肝炎患者失代偿性肝硬化的贡献:一项国际研究

The contribution of alcohol use disorder to decompensated cirrhosis among people with hepatitis C: An international study.
PubMed 文献 · J Hepatol · 2017-10-26

该国际研究纳入加拿大不列颠哥伦比亚、澳大利亚新南威尔士和苏格兰的丙型肝炎病毒(HCV)通报人群,链接住院记录,评估酒精使用障碍对失代偿性肝硬化的贡献。三个地区中失代偿性肝硬化患者酒精使用障碍比例分别为28%、32%和50%,酒精使用障碍与失代偿性肝硬化独立相关(aHR分别为1.92、3.68、3.88),归因分数分别为13%、25%和40%。

要点

  • HCV人群中失代偿性肝硬化患者合并酒精使用障碍的比例在三个地区为28%至50%。
  • 酒精使用障碍与失代偿性肝硬化独立相关,aHR在不列颠哥伦比亚为1.92,新南威尔士为3.68,苏格兰为3.88。
  • 酒精使用障碍相关失代偿性肝硬化的归因分数在不列颠哥伦比亚为13%,新南威尔士为25%,苏格兰为40%。

核心结论

  • 酒精使用障碍在所有研究地区均是HCV肝病负担的主要贡献因素,在苏格兰尤为突出。
  • 酒精使用对直接抗病毒药物(DAA)治疗在个体和人群水平获益的损害程度需密切监测。
  • 为达成世界卫生组织2030年HCV死亡率下降目标,各国应在适宜情况下制定策略,将促进DAA治疗 uptake 与酒精使用障碍管理相结合。

研究设计与样本

  • 国际研究,链接加拿大不列颠哥伦比亚(1995-2011年HCV通报,2001-2012年住院记录)、澳大利亚新南威尔士(1995-2012年通报,2001-2013年住院记录)和苏格兰(1995-2013年通报,2001-2014年住院记录)的HCV通报与住院记录。
  • 酒精使用障碍定义为因酒精使用导致的非肝相关住院。
  • 采用Cox回归评估相关因素,计算酒精使用障碍相关的人群归因分数(PAF)。
  • 样本量:不列颠哥伦比亚58,487人,新南威尔士84,529人,苏格兰31,924人。

主要发现

  • 失代偿性肝硬化诊断人数:不列颠哥伦比亚2,689人(4.6%),新南威尔士3,169人(3.7%),苏格兰1,375人(4.3%)。
  • 失代偿性肝硬化患者中酒精使用障碍比例:不列颠哥伦比亚28%,新南威尔士32%,苏格兰50%。
  • 年龄标准化失代偿性肝硬化发病率在新南威尔士和苏格兰的酒精使用障碍人群中 considerably higher。
  • 失代偿性肝硬化与酒精使用障碍独立相关:不列颠哥伦比亚aHR 1.92(95% CI 1.76-2.10),新南威尔士aHR 3.68(95% CI 3.38-4.00),苏格兰aHR 3.88(95% CI 3.42-4.40)。
  • 酒精使用障碍相关失代偿性肝硬化的PAF:不列颠哥伦比亚13%,新南威尔士25%,苏格兰40%。

关键数值与推荐

  • 酒精使用障碍定义为因酒精使用导致的非肝相关住院。
  • 失代偿性肝硬化与酒精使用障碍独立相关:不列颠哥伦比亚aHR 1.92(95% CI 1.76-2.10),新南威尔士aHR 3.68(95% CI 3.38-4.00),苏格兰aHR 3.88(95% CI 3.42-4.40)。
  • 酒精使用障碍相关失代偿性肝硬化的PAF:不列颠哥伦比亚13%,新南威尔士25%,苏格兰40%。

临床怎么用

  • 作者指出,酒精使用障碍在所有研究地区均是HCV肝病负担的主要贡献因素,在苏格兰尤为突出。
  • 作者指出,需密切监测酒精使用对DAA治疗在个体和人群水平获益的损害程度。
  • 作者建议,各国应在适宜情况下制定策略,将促进DAA治疗 uptake 与酒精使用障碍管理相结合,以达成世界卫生组织2030年HCV死亡率下降目标。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The advent of direct-acting antivirals (DAAs) has led to ambitious targets for hepatitis C virus (HCV) elimination. However, in the context of alcohol use disorder the ability of DAAs to achieve these targets may be compromised. The aim of this study was to evaluate the contribution of alcohol use disorder to HCV-related decompensated cirrhosis in three settings. METHODS: HCV notifications from British Columbia, Canada; New South Wales, Australia, and Scotland (1995-2011/2012/2013, respectively) were linked to hospital admissions (2001-2012/2013/2014, respectively). Alcohol use disorder was defined as non-liver-related hospitalisation due to alcohol use. Age-standardised decompensated cirrhosis incidence rates were plotted, associated factors were assessed using Cox regression, and alcohol use disorder-associated population attributable fractions (PAFs) were computed. RESULTS: Among 58,487, 84,529, and 31,924 people with HCV in British Columbia, New South Wales, and Scotland, 2,689 (4.6%), 3,169 (3.7%), and 1,375 (4.3%) had a decompensated cirrhosis diagnosis, and 28%, 32%, and 50% of those with decompensated cirrhosis had an alcohol use disorder, respectively. Age-standardised decompensated cirrhosis incidence rates were considerably higher in people with alcohol use disorder in New South Wales and Scotland. Decompensated cirrhosis was independently associated with alcohol use disorder in British Columbia (aHR 1.92; 95% CI 1.76-2.10), New South Wales (aHR 3.68; 95% CI 3.38-4.00) and Scotland (aHR 3.88; 95% CI 3.42-4.40). The PAFs of decompensated cirrhosis-related to alcohol use disorder were 13%, 25%, and 40% in British Columbia, New South Wales and Scotland, respectively. CONCLUSIONS: Alcohol use disorder was a major contributor to HCV liver disease burden in all settings, more distinctly in Scotland. The extent to which alcohol use would compromise the individual and population-level benefits of DAA therapy needs to be closely monitored. Countries, where appropriate, must develop strategies combining promotion of DAA treatment uptake with management of alcohol use disorders, if World Health Organization 2030 HCV mortality reduction targets are going to be achieved. LAY SUMMARY: The burden of liver disease has been rising among people with hepatitis C globally. The recent introduction of highly effective medicines against hepatitis C (called direct-acting antivirals or DAAs) has brought renewed optimism to the sector. DAA scale-up could eliminate hepatitis C as a public health threat in the coming decades. However, our findings show heavy alcohol use is a major risk factor for liver disease among people with hepatitis C. If continued, heavy alcohol use could compromise the benefits of new antiviral treatments at the individual- and population-level. To tackle hepatitis C as a public health threat, where needed, DAA therapy should be combined with management of heavy alcohol use.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Alavi M, Janjua NZ, Chong M, et al. The contribution of alcohol use disorder to decompensated cirrhosis among people with hepatitis C: An international study. J Hepatol. 2017. PMID: 29107152. doi:10.1016/j.jhep.2017.10.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。